## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($138.29)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bearish (Bullish: 0, Bearish: 4)

**1. Neurocrineâ€™s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial**
- Source: BioSpace | 20251223T080925 | Somewhat-Bearish | Relevance: 100%
- Neurocrine Biosciences' valbenazine, marketed as Ingrezza, failed to meet its primary and key secondary endpoints in a Phase III trial for dyskinetic cerebral palsy (DCP), a neurodevelopmental disorder. While disappointing due to the lack of approved treatments for DCP, analysts noted the setback had minimal impact on Neurocrine's overall valuation. The company continues to focus on its commercial products, Ingrezza for tardive dyskinesia and Huntington's disease, and Crenessity for congenital adrenal hyperplasia, alongside developing neuropsychiatry and early-stage obesity pipelines.

**2. Neurocrine Biosciences (NBIX): Assessing Valuation After New Phase 2 Bipolar I Mania Trial Launch**
- Source: Simply Wall Street | 20251222T150952 | Somewhat-Bullish | Relevance: 100%
- Neurocrine Biosciences (NBIX) has initiated a Phase 2 trial for NBI-1117568 in Bipolar I manic episodes, which has positively impacted investor sentiment. Despite its shares trading at a discount to Wall Street targets and showing double-digit revenue and earnings growth, its high P/E ratio compared to the industry raises questions about whether its growth potential is already priced in. The company's fair value is estimated at $244.80, suggesting it is undervalued, but this depends on the success of trials and manageable pricing pressures.

**3. Neurocrine's Phase 3 Trial of Valbenazine in Dyskinetic Cerebral Palsy Fails to Meet Primary, Key Secondary Endpoints**
- Source: marketscreener.com | 20251222T043700 | Bearish | Relevance: 100%
- Neurocrine Biosciences announced that its Phase 3 trial of valbenazine for dyskinetic cerebral palsy did not achieve its primary or key secondary endpoints. This news led to a movement disorder treatment failing in a late-stage trial. Despite this setback, the company continues its diverse portfolio development.

**4. Voya Investment Management LLC Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20251223T140925 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 25% in Q3, selling 30,462 shares to hold 91,278 shares valued at $12.8 million. This comes despite Neurocrine beating Q3 earnings expectations with $2.17 EPS and strong revenue growth, leading to multiple analyst price target increases and a "Moderate Buy" rating. Insider selling has been notable, with 43,866 shares sold for $6.57 million in the last 90 days, even as institutional ownership remains high at 92.59%.

**5. Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy**
- Source: PR Newswire | 20251223T080952 | Bearish | Relevance: 100%
- Neurocrine Biosciences announced that its Phase 3 KINECT-DCP study for valbenazine in pediatric and adult participants with dyskinetic cerebral palsy (DCP) did not meet its primary or key secondary endpoints. The study aimed to assess the improvement of chorea, a type of involuntary movement, in individuals with DCP. Despite the disappointing results, the company expressed gratitude to participants and investigators, and plans to present full study results at a future scientific meeting.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | HC Wainwright & | $198 | $168 | +18% |
| 2025-12-12 | Mizuho | $175 | $146 | +20% |
| 2025-12-11 | Stifel | $188 | $183 | +3% |
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | HC Wainwright & | main | Buy |
| 2025-12-12 | Mizuho | main | Neutral |
| 2025-12-11 | Stifel | main | Buy |
| 2025-12-08 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 10 ($2.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +13%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 16.0x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (5 raises, avg +13%). Insider selling cluster ($3.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.6B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 16.0 |
| Current P/E | 21.2 |
| YoY Growth | 32.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -5.2% to -2.3% (+2.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.3pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-0.93), momentum weakening. RSI neutral at 48. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.26% (CS: 21) | Weak |
| RSI_14 | 47.8 | Neutral |
| MACD Histogram | -0.93 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 1.128x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $146.93
- **Stop Loss:** $138.29 (5.9% risk)
- **Target:** $155.57 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 138
- **Position Value:** $20,276.34
- **Portfolio %:** 20.28%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*